Ghulam Awan, MD
Cardiovascular Disease · Mobile, ALNPI 1760431662
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.5%), food and beverage and grants — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Abbott at 46.0% of the total. Reporting peaked in 2023 at $3,612 and has fallen 94.7% since, to $191 in 2025.
Across 134 payments — averaging $69.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Medtronic$4K
- Boston Scientific$466
- Amgen$68
- Philips North America LLC$65
- Cardiovascular Systems Inc.$58
- plus $405 from 15 others
Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$500
What the payments were for
- Consulting fees$1412%
- Grants$3334%
- Travel & lodging$5,17055%
- Food & beverage$3,67839%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 54 | $4,293 |
| Medtronic(2 entities) | 33 | $3,968 |
| Boston Scientific | 13 | $466 |
| Amgen | 5 | $68 |
| Philips North America LLC | 2 | $65 |
| Cardiovascular Systems Inc. | 3 | $58 |
| Novartis | 2 | $48 |
| Bard Peripheral Vascular, Inc. | 2 | $43 |
| Johnson & Johnson | 3 | $42 |
| AstraZeneca | 3 | $39 |
| Route 92 Medical, Inc. | 1 | $37 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $36 |
| Gilead | 2 | $25 |
| Pfizer | 2 | $24 |
| Z-medica, LLC | 1 | $23 |
| Abiomed | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Lantheus Medical Imaging, Inc. | 1 | $15 |
| Terumo Medical Corporation | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
| GE HealthCare | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaSeal$1,569
- Omnilink Elite vascular stent system$1,433
- SUPERA$974
- Micra$727
- CoreValve Evolut$705
- AMPLATZER Occluders$540
- GENERAL - STENTS$124
- Supera peripheral stent system$109
How this compares
$9,323 in reported general payments places this provider in the 80th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 100 | $74,738 |
| EntrestoSacubitril/Valsartan | 25 | $33,803 |
| BrilintaTicagrelor | 15 | $12,161 |
| FarxigaDapagliflozin Propanediol | 14 | $9,135 |
| Rosuvastatin Calcium | 77 | $1,884 |
| Atorvastatin Calcium | 95 | $1,545 |
| Torsemide | 28 | $997 |
| Metoprolol Succinate | 80 | $923 |
| ClopidogrelClopidogrel Bisulfate | 52 | $790 |
| Carvedilol | 71 | $778 |
| Ezetimibe | 26 | $706 |
| Fosinopril Sodium | 17 | $659 |
| Warfarin Sodium | 45 | $555 |
| Amlodipine Besylate | 57 | $440 |
| Pantoprazole Sodium | 28 | $375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $24 | $74,738100 claims |
| NovartisEntresto | $48 | $33,80325 claims |
| AstraZenecaBrilinta, Farxiga | $39 | $21,29629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Mobile
- Dennis ThomasMobile$894K
- Michael RihnerMobile$13K
- David FienoAlabaster$421K
- Vikram AroraBirmingham$271K
- Jason ThompsonBirmingham$248K
- Michael WilenskyBirmingham$241K
- Mustafa AhmedBirmingham$218K
- Frederick GaskinBirmingham$115K
- Pankaj AroraBirmingham$83K
- Ajit NaiduFlorence$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.